tiprankstipranks
Advertisement
Advertisement
Bicycle Therapeutics Reports Positive Duravelo-2 Phase 2 Data
PremiumCompany AnnouncementsBicycle Therapeutics Reports Positive Duravelo-2 Phase 2 Data
3M ago
Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies
Premium
The Fly
Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies
4M ago
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
Premium
Ratings
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
4M ago
Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
PremiumThe FlyBicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
5M ago
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
Premium
Ratings
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
5M ago
Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital
Premium
The Fly
Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital
5M ago
BCYC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsBCYC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
Bicycle Therapeutics CFO Alethia Young steps down, Travis Thompson succeeds
Premium
The Fly
Bicycle Therapeutics CFO Alethia Young steps down, Travis Thompson succeeds
7M ago
Bicycle Therapeutics CMO Eric Westin retires, Michael Method succeeds
Premium
The Fly
Bicycle Therapeutics CMO Eric Westin retires, Michael Method succeeds
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100